COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination CampaignPublic Health Published on 2024-01-242024-09-05 Journal: Cureus [Category] update2024, [키워드] Autoimmune cardiovascular COVID-19 mRNA vaccines gene therapy products Immunity Mortality registrational trials risk-benefit assessment sars-cov-2 (severe acute respiratory syndrome coronavirus -2) Serious Adverse Events [DOI] 10.7759/cureus.52876 PMC 바로가기 [Article Type] Public Health
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé omicron Omicron variant overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunityArticle Published on 2022-11-012022-11-15 Journal: Annals of allergy, asthma & immunology : official [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] antibody Antibody Response Autoimmune clinical trial clinician Combination Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine criteria detectable Diagnosis Evidence Factor healthy controls immune immune dysregulation Immunity immunodeficiency immunogenic individuals literature Messenger RNA Patient performed reactogenicity response Safe Safety SARS-CoV-2 Serious Adverse Events subjects T cell response vaccination Vaccinations Vaccine [DOI] 10.1016/j.anai.2022.06.009 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials소아 및 청소년에 대한 COVID-19 백신의 안전성 및 효능: 무작위 대조 시험의 체계적인 검토Review Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] Fulltext, MERS, 임상, [키워드] Abstract age Analysis bias risk children Children and adolescents Chinese clinical clinical trial Cochrane Library code common adverse event common adverse events coronavirus coronavirus disease cough COVID-19 COVID-19 infection COVID-19 vaccine COVID-19 vaccines data extraction Efficacy evaluated fatigue Fever groups headache ICTRP immunization Injection-site pain investigated Local Messenger RNA Microsoft Excel Mild mild to moderate moderate MOST mRNA mRNA vaccine mRNA vaccines muscle pain Pain participant pediatric Placebo profile Randomized controlled trial Randomized controlled trials RCT RCTs reaction Reactions registry reported Safety searched Serious Adverse Events Seven stratified suggested systematic review systemic adverse event the vaccine title Trial vaccination Vaccine was used Web of Science website were used [DOI] 10.1002/jmv.27940 PMC 바로가기 [Article Type] Review